摘要
维持性血液透析(MHD)患者通常会并发继发性甲状旁腺功能亢进(SHPT),SHPT主要是由于机体长期受到低血钙、低血镁或高血磷刺激下而产生的甲状旁腺增生肥大或甲状旁腺激素(PTH)分泌过多及钙磷代谢紊乱的临床综合征,临床症状表现为骨痛、病理性骨折、皮肤瘙痒等。采取恰当的治疗可对SHPT高磷血症、维持血钙和甲状旁腺素水平进行有效控制,降低MHD患者死亡率。目前临床上主要应用新型磷结合剂、维生素D类似物及钙敏感受体激活剂治疗,且临床疗效显著。现综述MHD伴SHPT发病机制及其治疗价值的最新研究进展。
Maintenance hemodialysis patients usually have secondary hyperparathyroidism(SHPT).SHPT is mainly a clinical syndrome of hyperplasia of parathyroid glands or hypersecretion of parathyroid hormone(PTH)and disorder of calcium and phosphorus metabolism caused by long-term stimulation of hypocalcemia,hypomagnesium or hyperphosphate,the clinical symptoms are bone pain,pathological fracture,itchy skin and so on.Appropriate treatment can effectively control hyperphosphatemia,maintain blood calcium and parathyroid hormone levels in patients with SHPT,and reduce mortality in maintenance hemodialysis(MHD)patients.At present,new phosphorus binders,vitamin D analogs and calcium-sensitive receptor activators are mainly used in clinical treatment,and clinical efficacy is significant.This article reviews the latest research progress in the pathogenesis of MHD with SHPTand its therapeutic value.
作者
张民霞
ZHANG Min-xia(Department of Hemodialysis Room,Tianjin Jinghai District Hospital,Tianjin 301600,China)
出处
《现代诊断与治疗》
CAS
2020年第16期2551-2553,共3页
Modern Diagnosis and Treatment